BERNARDSVILLE, N.J., April 26, 2023 (GLOBE NEWSWIRE) — Anima Biotech, the leader in the discovery of small molecule mRNA drugs and their mechanisms of action by phenotypic screening with AI driven MOA elucidation, announced today the launch of a groundbreaking webinar series in partnership with leading life science media outlets. The series will provide up-to-date, high-quality information on mRNA biology, a game-changing approach that is revolutionizing drug discovery and opening doors to new therapeutic possibilities.
The pharmaceutical industry is eagerly exploring mRNA biology as a major wave of innovation, but the field is complex and not well understood. Anima Biotech’s webinar series aims to bridge this knowledge gap by providing valuable insights into the latest advancements in mRNA regulation research and their impact on drug discovery. By partnering with leading life science media outlets, Anima Biotech is committed to delivering high-quality, free educational content that will drive innovation in drug discovery and ultimately benefit patients worldwide.
The webinar series will cover a range of topics, including mRNA regulation pathways and target space, approaches to discover and validate mechanisms of action and novel targets, and the development of cutting-edge technologies tailored to specific stages of the mRNA life cycle. Anima Biotech is excited to partner with Endpoints for its first webinar in the series, “Exposing Hidden Targets within the mRNA Regulation Space,” which will feature Anima Biotech’s chief scientific officer and co-founder, Iris Alroy, Ph.D., and Michael Kharas, Ph.D., a world-renowned cancer biologist and expert in RNA regulation from Memorial Sloan Kettering Cancer Center.
During the webinar, Drs. Alroy and Kharas will discuss the latest advancements in mRNA regulation research and the impact of these findings on drug discovery. The webinar will delve into the complex and finely tuned processes of mRNA regulation, exploring how a deeper comprehension of the regulatory mechanisms governing mRNA translation can uncover new targets for drug discovery and therapeutic intervention.
To register for the free webinar, please visit https://webinars.endpts.com/exposing-hidden-targets-within-the-mrna-regulation-space/.
About Anima Biotech
Anima Biotech is advancing mRNA Lightning, a novel platform for the discovery of small molecule mRNA drugs and their mechanisms of action. Our differentiated approach combines high scale phenotypic screening that automates millions of experiments in live mRNA biology with MOAi technology using AI to elucidate the mechanism of action of active molecules. Our approach has been validated by our collaborations with Lilly, Takeda Pharmaceuticals and AbbVie and a broad pipeline across 20 different discovery programs in various therapeutic areas. With our deep expertise in mRNA biology, we were able to advance our programs at an unprecedented speed and success rate. Anima’s wholly owned pipeline is in Immunology (Collagen I mRNA biology modulators, preclinical stage in lung fibrosis and applicable across many fibrotic diseases), Oncology (c-Myc mRNA biology modulators and mutation agnostic mKras mRNA biology modulators), and Neuroscience (Tau – Alzheimer’s disease and Pain – Nav1.7 mRNA biology modulators). Our science was further validated with seven patents, 15 peer-reviewed publications and 17 scientific collaborations. For more information about Anima Biotech, please visit our website at https://www.animabiotech.com and follow us on LinkedIn and Twitter at @AnimaBiotech.
Media Contact:
Andrew Mielach
LifeSci Communications
+1.646.876.5868
[email protected]
Stay connected with us on social media platform for instant update click here to join our Twitter, & Facebook
We are now on Telegram. Click here to join our channel (@TechiUpdate) and stay updated with the latest Technology headlines.
For all the latest Health News Click Here
For the latest news and updates, follow us on Google News.
Denial of responsibility! NewsAzi is an automatic aggregator around the global media. All the content are available free on Internet. We have just arranged it in one platform for educational purpose only. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to their authors. If you are the owner of the content and do not want us to publish your materials on our website, please contact us by email – [email protected]. The content will be deleted within 24 hours.
